Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
Key Sessions

Paul Csiszár

Update from EU Commission on Competition Law Enforcement

DG Competition, European Commission, Belgium

May 21
Show Filter
08:00 - 08:50

Registration

More
Showing of Streams
10:40 - 11:10

Networking Break

More
Showing of Streams
12:40 - 14:10

Networking Lunch Break

More
Showing of Streams
15:30 - 16:00

Networking Break

More
Showing of Streams
17:25 - 18:15

Networking Drinks Reception

More
Showing of Streams
20:15 - 21:15

Networking Dinner

More
08:00 - 08:50 50 mins
Registration
08:50 - 09:00 10 mins
Competition Law and Patent Litigation
Introduction from Chairperson
  • Mélanie Thill-Tayara - Antitrust/Competition Partner, Dechert LLP, France
09:00 - 09:40 40 mins
Info
Competition Law and Patent Litigation
Update from EU Commission on Competition Law Enforcement
  • Paul Csiszár - Director, DG Competition, European Commission, Belgium
  • Recent updates in the EU pharmaceutical Law sector on competition law enforcement
  • Insight into abusive dominance through excessive pricing
  • Latest developments on reverse payment settlements
09:40 - 10:40 60 mins
Info
Competition Law and Patent Litigation
INTERACTIVE DISCUSSION FORUM: Excessive Pricing in the Pharmaceutical Industry
  • Ingrid Vandenborre - Partner, Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates, Belgium
  • Wolf Sauter - Expert, Netherlands Authority for Consumers and Markets (ACM), The Netherlands
  • Molly Herron - Senior Legal Counsel, Antitrust EMEA, Novartis International AG, Switzerland
  • Avantika Chowdhury - Partner, Oxera LLP, UK
  • Update on abusive dominance through excessive pricing case law
  • Practical advice following decisions and developments in recent cases
  • What constitutes excessive: identifying appropriate value indicators for originator products and understanding value to whom and compared to what
10:40 - 11:10 30 mins
Networking Break
11:10 - 12:10 60 mins
Info
Competition Law and Patent Litigation
INTERACTIVE DISCUSSION FORUM: Reverse Payment Patent Settlements
  • Geoff Steadman - Project Director, Competition & Markets Authority (CMA), UK
  • Rainer Becker - Head of Unit, DG Competition, European Commission, Belgium
  • James Killick - Partner, White & Case LLP, Belgium
  • Insight into the Lundbeck and Servier case: practical implications for patent settlements and market definition
  • Acquisitions of technology: can this be considered an abuse of a dominant position?
  • How do you define the relevant market from a competition law perspective to define dominance?
12:10 - 12:40 30 mins
Info
Competition Law and Patent Litigation
Update on Parallel Trade in a Post Brexit Era
  • Jacob Westin - Legal Counsel, Shire Pharmaceuticals, Sweden
  • Recent competition law rulings and case law for parallel trade: update on dual pricing
  • Drivers of parallel trade across Europe, key risks and implications
  • Exploring the impact of Brexit on the EU market and parallel trade practices
  • Models and approaches for pharmaceutical companies: what opportunities and risks will Brexit offer?
12:40 - 14:10 90 mins
Networking Lunch Break
14:10 - 14:50 40 mins
Info
Competition Law and Patent Litigation
DUAL DIALOGUE: Examining Product Hopping: Abusive Dominance or Product Innovation?
  • David Hull - Partner, Van Bael & Bellis LLP, Belgium
  • Angela Staunton - Vice President, Law, Patents & Compliance – Pharmaceuticals, Bayer Healthcare AG, Germany
  • Examining cases, rulings and review for product hopping as a lifecycle management strategy
  • Update on the expansion of antitrust scrutiny on product lifecycle strategies
  • Strategies to minimise competition law risks and protect your product
14:50 - 15:30 40 mins
Info
Competition Law and Patent Litigation
INTERACTIVE DISCUSSION FORUM: Assessing the Current Status of SPCs
  • Brian Cordery - Partner, Bristows LLP, UK
  • Nicolas Ruiz - Intellectual Property Head, European Patent Attorney, Esteve, Spain
  • Update on the law of “protected by a basic patent force”: how is Gilead being applied by National Courts and Patent Offices? Royalty Pharma and Janssen references
  • The latest on SPCs based on 3rd party Mas: what is the direction of travel?
  • SPCs for novel and inventive formulations: the Abraxis decision
  • SPCs for medical devices and combined medical devices/medicinal products – the CJEU decision in Boston Scientific
  • Reform of SPC law - the Max Planck report and other initiatives: evaluating the proposed manufacturing exemption
15:30 - 16:00 30 mins
Networking Break
16:00 - 16:40 40 mins
Info
Competition Law and Patent Litigation
DUAL DIALOGUE: Patent Relief - Injunctions, Arrow Declarations, Cross Border Declarations and Injunctions
  • Benoît Strowel - Managing Partner, Hoyng Rokh Monegier LLP, Belgium
  • Paul Inman - Partner, Gowling WLG LLP, UK
  • Examining recent trends in the granting of relief by the major European Patents Courts
  • Are final injunctions no longer to be the norm following a finding that a patent is valid and infringed?
  • What role could compulsory licences pay?
  • Cross-border relief
  • Update on Arrow declarations
16:40 - 17:20 40 mins
Info
Competition Law and Patent Litigation
DUAL DIALOGUE: Second Medical Use Patents
  • Hiroshi Sheraton - Partner, Baker & McKenzie LLP, UK
  • Jennifer Sunderland - Senior Patent Litigation Counsel, Global Litigation, Mylan, UK
  • Examining the UKSC decision in the pregabalin case and the implications for plausibility, amendment of patents and cross-label use
  • Practical steps to be taken when enforcing a second medical use patent
  • How much data needs to be included in a patent? How to find the sweet-spot in which to file an application
17:20 - 17:25 5 mins
Competition Law and Patent Litigation
Chairperson’s Closing Remarks
17:25 - 18:15 50 mins
Networking Drinks Reception
20:15 - 21:15 60 mins
Networking Dinner